CoMentis (Drug Discovery) Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Out of Business

  • Employees
  • 33

Employees

  • Latest Deal Type
  • Liquidation

CoMentis (Drug Discovery) General Information

Description

Developer of small-molecule drugs designed to treat central nervous system disorders. The company's drugs cover the research and development spectrum from initial drug design through manufacturing and clinical trials, enabling healthcare professionals to treat age-related macular degeneration (AMD) and other cognitive disorders easily.

Contact Information

Formerly Known As
Athenagen
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 400 Oyster Point Boulevard
  • Suite 226
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 400 Oyster Point Boulevard
  • Suite 226
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CoMentis (Drug Discovery) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Bankruptcy: Liquidation 01-Jun-2017 Completed Out of Business
5. Later Stage VC (Series E) 16-Mar-2016 Completed Generating Revenue
4. Later Stage VC (Series D) 15-May-2008 Completed Generating Revenue
3. Later Stage VC (Series C) 24-Oct-2007 Completed Generating Revenue
2. Early Stage VC (Series B) 06-Sep-2007 $50M $71M Completed Generating Revenue
1. Early Stage VC (Series A) 11-Aug-2006 $21M $21M Completed Generating Revenue
To view CoMentis (Drug Discovery)’s complete valuation and funding history, request access »

CoMentis (Drug Discovery) Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D
Series C
Series B 92,543,030 $0.000100 8.5% $0.43 $0.43 1x $0.43 37.51%
Series A 34,669,123 $0.000100 8.5% $0.47 $0.47 1x $0.47 14.05%
To view CoMentis (Drug Discovery)’s complete cap table history, request access »

CoMentis (Drug Discovery) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small-molecule drugs designed to treat central nervous system disorders. The company's drugs cover the rese
Drug Discovery
South San Francisco, CA
33 As of 2015

Milwaukee, WI
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CoMentis (Drug Discovery) Competitors (50)

One of CoMentis (Drug Discovery)’s 50 competitors is Promentis Pharmaceuticals, a Venture Capital-Backed company based in Milwaukee, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Promentis Pharmaceuticals Venture Capital-Backed Milwaukee, WI
Genentech Formerly VC-backed South San Francisco, CA
Mitochon Pharmaceuticals Venture Capital-Backed Blue Bell, PA
Metabolic Solutions Development Company Venture Capital-Backed Kalamazoo, MI
Alzheon Venture Capital-Backed Framingham, MA
You’re viewing 5 of 50 competitors. Get the full list »

CoMentis (Drug Discovery) Patents

CoMentis (Drug Discovery) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2013267555-A1 Chromane compounds Inactive 30-May-2012
CA-2873678-A1 Chromane compounds Inactive 30-May-2012
EP-2854797-A2 Chromane compounds Inactive 30-May-2012
EP-2854797-A4 Chromane compounds Inactive 30-May-2012
US-20140179695-A1 Chromane compounds Active 30-May-2012 C07D413/14
To view CoMentis (Drug Discovery)’s complete patent history, request access »

CoMentis (Drug Discovery) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CoMentis (Drug Discovery) Investments & Acquisitions (3)

CoMentis (Drug Discovery)’s most recent deal was a Early Stage VC with Soyhuce for . The deal was made on 01-May-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Soyhuce 01-May-2017 Early Stage VC IT Consulting and Outsourcing
Zapaq 14-Aug-2006 Merger/Acquisition Drug Discovery
Osprey Pharmaceutical Company 13-Apr-2006 Merger/Acquisition Drug Discovery
To view CoMentis (Drug Discovery)’s complete investments and acquisitions history, request access »

CoMentis (Drug Discovery) FAQs

  • When was CoMentis (Drug Discovery) founded?

    CoMentis (Drug Discovery) was founded in 2004.

  • Where is CoMentis (Drug Discovery) headquartered?

    CoMentis (Drug Discovery) is headquartered in South San Francisco, CA.

  • What is the size of CoMentis (Drug Discovery)?

    CoMentis (Drug Discovery) has 33 total employees.

  • What industry is CoMentis (Drug Discovery) in?

    CoMentis (Drug Discovery)’s primary industry is Drug Discovery.

  • Is CoMentis (Drug Discovery) a private or public company?

    CoMentis (Drug Discovery) is a Private company.

  • What is CoMentis (Drug Discovery)’s current revenue?

    The current revenue for CoMentis (Drug Discovery) is .

  • How much funding has CoMentis (Drug Discovery) raised over time?

    CoMentis (Drug Discovery) has raised $108M.

  • Who are CoMentis (Drug Discovery)’s competitors?

    Promentis Pharmaceuticals, Genentech, Mitochon Pharmaceuticals, Metabolic Solutions Development Company, and Alzheon are some of the 50 competitors of CoMentis (Drug Discovery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process